Antihemophilic factor (recombinant), glycopegylated-exei - Biologic Drug Details

Summary for antihemophilic factor (recombinant), glycopegylated-exei

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antihemophilic factor (recombinant), glycopegylated-exei Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antihemophilic factor (recombinant), glycopegylated-exei Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671	7,199,223	2024-02-26	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671	8,133,977	2029-12-11	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671	8,143,378	2029-12-11	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671	8,247,536	2029-12-11	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671	8,536,126	2033-02-05	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671	9,150,848	2034-05-08	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for antihemophilic factor (recombinant), glycopegylated-exei Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for antihemophilic factor (recombinant), glycopegylated-exei

Country	Patent Number	Estimated Expiration
European Patent Office	1596887
Taiwan	201412333
Poland	2257311
France	22C1043
Russian Federation	2010137743
Denmark	2257311
Japan	5619630

Supplementary Protection Certificates for antihemophilic factor (recombinant), glycopegylated-exei

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2019/050	Ireland		PRODUCT NAME: TUROCTOCOG ALFA PEGOL; REGISTRATION NO/DATE: EU/1/19/1374/001-005 20190624
60/2019	Austria		PRODUCT NAME: TUROCTOCOG ALFA PEGOL; REGISTRATION NO/DATE: EU/1/19/1374 (MITTEILUNG) 20190624
2019C/549	Belgium		PRODUCT NAME: TUROCTOCOG ALFA PEGOL; AUTHORISATION NUMBER AND DATE: EU/1/19/1374/001-005 20190624
301184	Netherlands		PRODUCT NAME: RURIOCTOCOG ALFA PEGOL; REGISTRATION NO/DATE: EU/1/17/1247 20180110
CA 2019 00040	Denmark		PRODUCT NAME: TUROCTOCOG ALFA PEGOL; REG. NO/DATE: EU/1/19/1374 20190624
122019000103	Germany		PRODUCT NAME: TUROCTOCOG ALFA PEGOL; REGISTRATION NO/DATE: EU/1/19/1374 20190620
698	Finland

Antihemophilic factor (recombinant), glycopegylated-exei Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Dynamics and Financial Trajectory for Antihemophilic Factor (Recombinant), Glycopegylated-Exei

Market Overview

Antihemophilic factor (recombinant), glycopegylated-exei, is a glycoPEGylated recombinant factor VIII used to treat hemophilia A. Its development targets improving pharmacokinetics and reducing infusion frequency, addressing major limitations of traditional factor VIII therapies.

Market Drivers

Unmet Medical Need: Hemophilia A requires lifelong, regular factor VIII infusions. GlycoPEGylation extends half-life from approximately 12 hours to up to 19 hours, reducing infusion frequency from thrice-weekly to twice-weekly or less (1).

Growth in Hemophilia Population: The global hemophilia A population exceeds 250,000 and is expected to grow at approximately 2.7% annually due to increased diagnosis rates and improved survival (2).

Advances in Biologics: Innovation in glycoengineering improves drug half-life and tolerability, making these therapies more attractive to healthcare providers and patients.

Pricing Dynamics: High-cost biologics see significant premiums; glycoPEGylated agents command premium pricing based on extended dosing intervals and reduced treatment burdens.

Market Barriers

Pricing and Reimbursement: High acquisition costs limit adoption in lower-income markets. Reimbursement policies vary, impacting revenue recognition.

Competition: Other long-acting factor VIII products, such as biocenters with albumin or Fc fusion, offer similar pharmacokinetics, intensifying market competition (3).

Regulatory Hurdles: Approval processes involve rigorous safety evaluations, particularly concerning PEG-related immune responses.

Patient and Physician Acceptance: Transitioning from established therapies to new options depends on demonstrating safety, efficacy, and convenience benefits.

Competitive Landscape

Company	Product Name	Half-life Extension	Market Share (Estimate)	Regulatory Status
Roche/Genentech	Esperoct (GlycoPEGylated FVIII)	1.5-2x	40%	Approved globally, 2019
Bioverativ (Lilly)	Eloctate (Fc fusion)	~1.5x	35%	Approved globally, 2014
Novo Nordisk	Esperoct	Similar to Roche	15%	Approved, 2019
Others	Various glycoengineering agents	Varies	10%	Under development or approval

Financial Trajectory

Revenue Projections: Estimated sales of (USD 3-4) billion globally by 2030 for glycoPEGylated factor VIII products, with annual growth rates averaging 8-12% (4).

Pricing Strategy: The current average wholesale price (AWP) per infusion ranges from (USD 8,000) to (USD 12,000). GlycoPEGylation extends dosing intervals, reducing annual infusion numbers and costs, which supports premium pricing but requires clear clinical benefit confirmation.

Market Expansion: Growth is expected primarily in Europe and North America, where healthcare systems support high-cost biologics. Asia-Pacific markets may expand as access and diagnosis improve, though price sensitivity remains an issue.

Financial Risks

• Pricing pressure from biosimilars or alternative therapies.
• Regulatory changes that restrict high-cost biologic reimbursement.
• Patent expirations expected around 2030, likely introducing biosimilars that could erode market share.
• Manufacturing complexities increasing operational costs.

Future Outlook

Adoption of glycoPEGylated factor VIII depends on continued demonstration of safety, especially PEG immunogenicity concerns. The pipeline includes next-generation long-acting agents employing Fc or albumin fusion technologies, competing directly or complementing glycoPEGylation strategies.

Market expansion hinges on improvements in global healthcare access and the evolution of payor policies favoring value-based care. Pricing models aligned with clinical outcomes will influence revenue growth.

Key Takeaways

• GlycoPEGylated recombinant factor VIII addresses key patient needs by prolonging half-life, decreasing infusion frequency.
• Competition remains intense among long-acting biologics and biosimilars, influencing pricing and market share.
• Revenue growth is driven by increased diagnosis, improved treatment adherence, and premium pricing in developed markets.
• Regulatory and reimbursement environments pose risks, particularly regarding PEG immunogenicity and high treatment costs.
• The global hemophilia A market is expected to reach \$3-4 billion by 2030, with a compound annual growth rate of approximately 10%.

FAQs

1. What differentiates glycoPEGylated factor VIII from other long-acting products?
GlycoPEGylation increases the molecular size and reduces renal clearance of factor VIII, prolonging its half-life. Compared to Fc or albumin fusion, glycoPEGylation may have different immunogenic profiles and manufacturing considerations.

2. How does PEG immunogenicity impact product adoption?
While PEG-related immune responses are rare, they can lead to anti-PEG antibodies, potentially reducing efficacy or causing adverse reactions, necessitating ongoing safety monitoring.

3. When are biosimilars expected to enter the market?
Patent expirations for leading glycoPEGylated factor VIII products are projected around 2030, followed by biosimilar development, which could reduce prices and transform market dynamics.

4. What factors influence the pricing of long-acting factor VIII therapies?
Pricing depends on dosing frequency, manufacturing costs, added clinical benefits, and market competition. Payors assess value based on treatment adherence and overall health economic impact.

5. What role do emerging gene therapies play in this market?
Gene therapies aim to provide curative options, potentially reducing long-term demand for factor VIII products. Their approval could significantly alter the market landscape within the next decade.

---

Sources

1. The European Association for Haemophilia and Allied Disorders (2021). Hemophilia Treatment Market Overview.
2. World Federation of Hemophilia (2020). Global Hemophilia Data.
3. J. Hematol. Oncol. 2020;13:71. Next-generation long-acting factor VIII therapies.
4. MarketWatch (2022). Hemophilia A biologics market forecast.